Previous human studies have suggested that PGC1α expression and activity is inhibited in obesity and type 2 diabetes [35,36], which leads to a disturbance in mitochondrial oxidative capacity and decreased insulin sensitivity. Here, PPARGC1A is linked to type 2 diabetes mellitus.